Etan Orgel, MD, MS News

A CHLA clinical trial finds that N-acetylcysteine may be a promising next-generation therapy to reduce the risk of cisplatin-induced hearing loss.

The ambitions of pediatric researchers are global in scale: Beyond patients at their own hospital, they look to shape national and international standards for pediatric care.

A CHLA oncologist led a pivotal clinical trial leading to the approval of the first drug to prevent cisplatin hearing loss in children.

In the News - Awards and Honors - New Faces

Yervant Demirjian’s son is nearly free of leukemia. In gratitude, Demirjian has made a generous planned gift to Children’s Hospital Los Angeles.

Risk of detecting cancer cells decreased by 70% after one month of treatment

Researchers at Children’s Hospital Los Angeles led a multi-institutional study that pins down, for the first time, the actual risk of hearing loss from cisplatin, a common chemotherapy agent